Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| SEQUIA | Other Identifier | Alias Study Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to explore for the first time how the different ALK TKIs have been sequenced in real-world clinical practice and with which outcomes for Swedish lung cancer patients
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Swedish Anaplastic lymphoma kinase (ALK) positive Non-small cell lung cancer (NSCLC) patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| crizotinib | Drug | as provided in real world practice |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival (OS): Based on Treatment Cohort Groups | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. Results were reported for treatment cohort groups based on generation of ALK treatment and were as following: Group A1 = chemotherapy + crizotinib (first generation ALK TKI) + any second (2nd) generation ALK TKI; Group A2 = crizotinib + any 2nd generation ALK TKI; Group B1: chemotherapy + crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group B2 = crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group C1 = chemotherapy + crizotinib + any 2nd generation ALK TKI + lorlatinib (third generation ALK TKI); Group C2: crizotinib + any 2nd generation ALK TKI + lorlatinib and Group D1 = any 2nd generation ALK TKI + any other 2nd generation ALK TKI. | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Overall Survival: Based on Chemotherapy Status | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. Results were reported based on chemotherapy status. | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Overall Survival: Based on Central Nervous System (CNS) Metastases Status | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. In this outcome measure, participants were grouped on basis of their CNS-metastases status. | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of Treatment: Based on Treatment Cohort Groups | Duration of treatment was defined as number of days on treatment calculated based on pharmaceutical specialties in Sweden (FASS) recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. Results were reported for treatment cohort groups based on generation of ALK treatment and were as following: Group A1 = chemotherapy + crizotinib (first generation ALK TKI) + any second (2nd) generation ALK TKI; Group A2 = crizotinib + any 2nd generation ALK TKI; Group B1: chemotherapy + crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group B2 = crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group C1 = chemotherapy + crizotinib + any 2nd generation ALK TKI + lorlatinib (third generation ALK TKI); Group C2: crizotinib + any 2nd generation ALK TKI + lorlatinib and Group D1 = any 2nd generation ALK TKI + any other 2nd generation ALK TKI. |
Not provided
Inclusion Criteria:
-Inclusion criteria for ALK-positive NSCLC patients will be based on prescription data i.e. defines eligible patients as adult patients with at least one filled prescription of ALK-inhibitors identified by the national prescription register. Only prescriptions filled at pharmacies can be captured in prescription registers, as they do not include data on hospital drugs. ALK-inhibitor treatments for patients with NSCLC are given primarily outside of the hospital setting minimizing the selection bias under the inclusion criteria.
Exclusion Criteria:
-not applicable
Not provided
Not provided
Not provided
Adult patients treated with ALK TKIs in Sweden between 2012 and 2019, identified via the national prescription register.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Innovations AB | Sollentuna | 19190 | Sweden |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
According to application sent to ethical counsel for this study, it was pre-planned not to report data for those cohorts/groups which had less than (<) 5 participants at the index date. Hence, due to ethical compliance study team ensured results would only be displayed on an aggregate level for reporting arms having greater than or equal to (>=) 5 participants at index date.
Study population included participants aged greater than or equal to 18 years at index date (date of first ALK TKI prescription), with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who had at least one filled prescription of ALK tyrosine kinase inhibitors (TKI) registered in the Swedish Prescribed Drug Register, between 01-Jan-2012 to 31-Dec-2020. Data of eligible participants were assessed in approximately 3 months of this retrospective observational study.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Participants With No First Line Chemotherapy | Participants included in this arm received at least one filled prescription of ALK TKIs in real world practices, with no first line chemotherapy treatment. ALK TKIs were crizotinib, alectinib, brigatinib, ceritinib, or lorlatinib. |
| FG001 | Participants With First Line Chemotherapy |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 3, 2020 |
Not provided
Not provided
Not provided
Not provided
| alectinib | Drug | as provided in real world practice |
|
| brigatinib | Drug | as provided in real world practice |
|
| ceritinib | Drug | as provided in real world practice |
|
| lorlatinib | Drug | as provided in real world practice |
|
| Overall Survival: Based on ALK Sequencing, 1 Line of ALK TKI Treatment | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. In this outcome measure, OS was reported for participants who received 1 line of ALK TKI treatment. Reporting arms were based on type of ALK TKI, with or without chemotherapy. ALK TKIs considered were crizotinib, alectinib, ceritinib. | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Overall Survival: Based on ALK Sequencing, 2 Lines of ALK TKI Treatment | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. In this outcome measure OS was reported for participants who received 2 lines of ALK TKI treatment. Reporting arms were based on type of first line ALK TKI treatment and second line of ALK TKI treatment, with or without chemotherapy. | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Overall Survival: Based on ALK Sequencing, 3 Lines of ALK TKI Treatment | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. In this outcome measure OS was reported for participants who received 3 lines of ALK inhibitor treatment. Reporting arms were based on type of first line ALK TKI treatment, second line of ALK TKI treatment and third line of ALK TKI treatment with or without, chemotherapy. | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Overall Survival: Based on ALK Sequencing, More Than or Equal to (>=) 4 Lines of ALK TKI Treatment | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. In this outcome measure, OS was reported for participants who received >=4 lines of ALK inhibitor treatment with or without chemotherapy. | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 5 Years From Index Date: Based on Treatment Cohort Groups | Results were reported for treatment cohort groups based on generation of ALK treatment and were as following: Group A1 = chemotherapy + crizotinib (first generation ALK TKI) + any second (2nd) generation ALK TKI; Group A2 = crizotinib + any 2nd generation ALK TKI; Group B1: chemotherapy + crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group B2 = crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group C1 = chemotherapy + crizotinib + any 2nd generation ALK TKI + lorlatinib (third generation ALK TKI); Group C2: crizotinib + any 2nd generation ALK TKI + lorlatinib and Group D1 = any 2nd generation ALK TKI + any other 2nd generation ALK TKI. | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 5 Years From Index Date: Based on Chemotherapy Status | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported in this outcome measure. Results were reported based on chemotherapy status. | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 5 Years From Index Date: Based on CNS Metastases Status | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported in this outcome measure. Results were reported based on CNS metastases status. | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, 1 Line of ALK TKI Treatment | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, participants who received 1 line of ALK TKI treatment, were reported. Reporting arms were based on type of first line ALK TKI treatment, with or without chemotherapy. ALK TKIs considered were crizotinib, alectinib, ceritinib. | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, 2 Lines of ALK TKI Treatment | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, participants who received 2 lines of ALK TKI treatment, were reported. Reporting arms were based on type of first line ALK TKI treatment and second line of ALK TKI treatment, with or without chemotherapy. | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, 3 Lines of ALK TKI Treatment | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, participants who received 3 lines of ALK TKI treatment. Reporting arms were based on type of first line ALK TKI treatment, second line of ALK TKI treatment, and third line of ALK TKI treatment, with or without chemotherapy. | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, More Than or Equal to (>=) 4 Lines of ALK TKI Treatment | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, data is reported for participants who received >=4 lines of ALK inhibitor treatment with or without chemotherapy. | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 6 Years From Index Date: Based on Treatment Cohort Groups | Results were reported for treatment cohort groups based on generation of ALK treatment and were as following: Group A1 = chemotherapy + crizotinib (first generation ALK TKI) + any second (2nd) generation ALK TKI; Group A2 = crizotinib + any 2nd generation ALK TKI; Group B1: chemotherapy + crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group B2 = crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group C1 = chemotherapy + crizotinib + any 2nd generation ALK TKI + lorlatinib (third generation ALK TKI); Group C2: crizotinib + any 2nd generation ALK TKI + lorlatinib and Group D1 = any 2nd generation ALK TKI + any other 2nd generation ALK TKI. | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 6 Years From Index Date: Based on Chemotherapy Status | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported in this outcome measure. Results were reported based on chemotherapy status. | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 6 Years From Index Date: Based on CNS Metastases Status | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported in this outcome measure. Results were reported based on CNS metastases status. | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 6 Years From Index Date: Based on ALK Sequencing, 1 Line of ALK TKI Treatment | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, participants who received 1 line of ALK TKI treatment, were reported. Reporting arms were based on type of first line ALK TKI treatment, with or without chemotherapy. ALK TKIs considered were crizotinib, alectinib, ceritinib. | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 6 Years From Index Date: Based on ALK Sequencing, 2 Lines of ALK TKI Treatment | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, participants who received 2 lines of ALK TKI treatment, were reported. Reporting arms were based on type of first line ALK TKI treatment and second line of ALK TKI treatment, with or without chemotherapy. | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 6 Years From Index Date: Based on ALK Sequencing, 3 Lines of ALK TKI Treatment | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure OS was reported for participants who received 3 lines of ALK inhibitor treatment. Reporting arms were based on type of first line ALK TKI treatment, second line of ALK TKI treatment, and third line of ALK TKI treatment, with or without chemotherapy. | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Percentage of Participants Alive After 6 Years From Index Date: Based on ALK Sequencing, More Than or Equal to (>=) 4 Lines of ALK TKI Treatment | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, data is reported for participants who received >=4 lines of ALK inhibitor treatment with or without chemotherapy. | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Duration of Treatment: Based on Chemotherapy Status | Duration of treatment was defined as number of days on treatment calculated based on pharmaceutical specialties in Sweden (FASS) recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. Results were reported based on chemotherapy status. | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI Treatment | Duration of treatment was defined as number of days on treatment calculated based on FASS recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. Reporting arms were based on type of ALK TKI, with or without chemotherapy. ALK TKIs considered were crizotinib, alectinib, ceritinib. | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Duration of Treatment: Based on ALK Sequencing, 2 Lines of ALK TKI Treatment | Duration of treatment was defined as number of days on treatment calculated based on FASS recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. Reporting arms were based on type of first line ALK TKI treatment, and second line of ALK TKI treatment, with or without chemotherapy. | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Duration of Treatment: Based on ALK Sequencing, 3 Lines of ALK TKI Treatment | Duration of treatment was defined as number of days on treatment calculated based on FASS recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. Reporting arms were based on type of first line ALK TKI treatment, second line of ALK TKI treatment, and third line of ALK TKI treatment with or without chemotherapy. | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| Duration of Treatment: Based on ALK Sequencing, More Than or Equal to (>=) 4 Lines of ALK TKI Treatment | Duration of treatment was defined as number of days on treatment calculated based on FASS recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. In this outcome measure, duration of treatment was reported for participants who received >=4 lines of ALK inhibitor treatment, with or without chemotherapy. | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
Participants included in this arm received at least one filled prescription of ALK TKIs in real world practices, along with first line chemotherapy treatment. ALK TKIs were crizotinib, alectinib, brigatinib, ceritinib, or lorlatinib. |
| COMPLETED |
|
| NOT COMPLETED |
|
Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Participants With No First Line Chemotherapy | Participants included in this arm received at least one filled prescription of ALK TKIs in real world practices, with no first line chemotherapy treatment. ALK TKIs were crizotinib, alectinib, brigatinib, ceritinib, or lorlatinib. |
| BG001 | Participants With First Line Chemotherapy | Participants included in this arm received at least one filled prescription of ALK TKIs in real world practices, along with first line chemotherapy treatment. ALK TKIs were crizotinib, alectinib, brigatinib, ceritinib, or lorlatinib. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary | Duration of Treatment: Based on Treatment Cohort Groups | Duration of treatment was defined as number of days on treatment calculated based on pharmaceutical specialties in Sweden (FASS) recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. Results were reported for treatment cohort groups based on generation of ALK treatment and were as following: Group A1 = chemotherapy + crizotinib (first generation ALK TKI) + any second (2nd) generation ALK TKI; Group A2 = crizotinib + any 2nd generation ALK TKI; Group B1: chemotherapy + crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group B2 = crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group C1 = chemotherapy + crizotinib + any 2nd generation ALK TKI + lorlatinib (third generation ALK TKI); Group C2: crizotinib + any 2nd generation ALK TKI + lorlatinib and Group D1 = any 2nd generation ALK TKI + any other 2nd generation ALK TKI. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure based on generation of ALK treatment. | Posted | Mean | Standard Deviation | Years | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
|
|
| ||||||||||||||||||||||||||||||||||||||||
| Secondary | Duration of Treatment: Based on Chemotherapy Status | Duration of treatment was defined as number of days on treatment calculated based on pharmaceutical specialties in Sweden (FASS) recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. Results were reported based on chemotherapy status. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. | Posted | Mean | Standard Deviation | Years | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI Treatment | Duration of treatment was defined as number of days on treatment calculated based on FASS recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. Reporting arms were based on type of ALK TKI, with or without chemotherapy. ALK TKIs considered were crizotinib, alectinib, ceritinib. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed (N)" signifies participants evaluable for this measure and received only 1 line of ALK TKIs with/ without chemotherapy. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had <5 participants at the index date. | Posted | Mean | Standard Deviation | Years | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Duration of Treatment: Based on ALK Sequencing, 2 Lines of ALK TKI Treatment | Duration of treatment was defined as number of days on treatment calculated based on FASS recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. Reporting arms were based on type of first line ALK TKI treatment, and second line of ALK TKI treatment, with or without chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. "Overall Number of Participants Analyzed (N)": participants evaluable for this measure and received only 2 lines of ALK TKIs with/ without chemotherapy. Groups with "N" =0: no participants with respective ALK TKI sequencing. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had <5 participants at the index date. | Posted | Mean | Standard Deviation | Years | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Duration of Treatment: Based on ALK Sequencing, 3 Lines of ALK TKI Treatment | Duration of treatment was defined as number of days on treatment calculated based on FASS recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. Reporting arms were based on type of first line ALK TKI treatment, second line of ALK TKI treatment, and third line of ALK TKI treatment with or without chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. "Overall Number of Participants Analyzed (N)": participants evaluable for this measure and received only 3 lines of ALK TKIs with/ without chemotherapy. Groups with "N" =0: no participants with respective ALK TKI sequencing. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had <5 participants at the index date. | Posted | Mean | Standard Deviation | Years | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Duration of Treatment: Based on ALK Sequencing, More Than or Equal to (>=) 4 Lines of ALK TKI Treatment | Duration of treatment was defined as number of days on treatment calculated based on FASS recommended dose for filled prescriptions of ALK-inhibitors taking permissible gap and stockpiling into account. In this outcome measure, duration of treatment was reported for participants who received >=4 lines of ALK inhibitor treatment, with or without chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and received >= 4 lines of ALK TKI treatment with or without chemotherapy. | Posted | Mean | Standard Deviation | Years | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Primary | Overall Survival (OS): Based on Treatment Cohort Groups | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. Results were reported for treatment cohort groups based on generation of ALK treatment and were as following: Group A1 = chemotherapy + crizotinib (first generation ALK TKI) + any second (2nd) generation ALK TKI; Group A2 = crizotinib + any 2nd generation ALK TKI; Group B1: chemotherapy + crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group B2 = crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group C1 = chemotherapy + crizotinib + any 2nd generation ALK TKI + lorlatinib (third generation ALK TKI); Group C2: crizotinib + any 2nd generation ALK TKI + lorlatinib and Group D1 = any 2nd generation ALK TKI + any other 2nd generation ALK TKI. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure based on generation of ALK treatment. | Posted | Median | 95% Confidence Interval | Years | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Primary | Overall Survival: Based on Chemotherapy Status | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. Results were reported based on chemotherapy status. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. | Posted | Median | 95% Confidence Interval | Years | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Primary | Overall Survival: Based on Central Nervous System (CNS) Metastases Status | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. In this outcome measure, participants were grouped on basis of their CNS-metastases status. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. | Posted | Median | 95% Confidence Interval | Years | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Primary | Overall Survival: Based on ALK Sequencing, 1 Line of ALK TKI Treatment | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. In this outcome measure, OS was reported for participants who received 1 line of ALK TKI treatment. Reporting arms were based on type of ALK TKI, with or without chemotherapy. ALK TKIs considered were crizotinib, alectinib, ceritinib. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed (N)" signifies participants evaluable for this measure and received only 1 line of ALK TKIs with/ without chemotherapy. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had <5 participants at the index date. | Posted | Median | 95% Confidence Interval | Years | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Primary | Overall Survival: Based on ALK Sequencing, 2 Lines of ALK TKI Treatment | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. In this outcome measure OS was reported for participants who received 2 lines of ALK TKI treatment. Reporting arms were based on type of first line ALK TKI treatment and second line of ALK TKI treatment, with or without chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. "Overall Number of Participants Analyzed (N)": participants evaluable for this measure and received only 2 lines of ALK TKIs with/ without chemotherapy. Groups with "N" =0: no participants with respective ALK TKI sequencing. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had <5 participants at the index date. | Posted | Median | 95% Confidence Interval | Years | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Primary | Overall Survival: Based on ALK Sequencing, 3 Lines of ALK TKI Treatment | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. In this outcome measure OS was reported for participants who received 3 lines of ALK inhibitor treatment. Reporting arms were based on type of first line ALK TKI treatment, second line of ALK TKI treatment and third line of ALK TKI treatment with or without, chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. "Overall Number of Participants Analyzed (N)": participants evaluable for this measure and received only 3 lines of ALK TKIs with/ without chemotherapy. Groups with "N" =0: no participants with respective ALK TKI sequencing. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had <5 participants at the index date. | Posted | Median | 95% Confidence Interval | Years | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Primary | Overall Survival: Based on ALK Sequencing, More Than or Equal to (>=) 4 Lines of ALK TKI Treatment | OS was defined as the time from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data). Kaplan-Meier method was used for analysis. In this outcome measure, OS was reported for participants who received >=4 lines of ALK inhibitor treatment with or without chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and received >= 4 lines of ALK TKI treatment with or without chemotherapy. | Posted | Median | 95% Confidence Interval | Years | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| ||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 5 Years From Index Date: Based on Treatment Cohort Groups | Results were reported for treatment cohort groups based on generation of ALK treatment and were as following: Group A1 = chemotherapy + crizotinib (first generation ALK TKI) + any second (2nd) generation ALK TKI; Group A2 = crizotinib + any 2nd generation ALK TKI; Group B1: chemotherapy + crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group B2 = crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group C1 = chemotherapy + crizotinib + any 2nd generation ALK TKI + lorlatinib (third generation ALK TKI); Group C2: crizotinib + any 2nd generation ALK TKI + lorlatinib and Group D1 = any 2nd generation ALK TKI + any other 2nd generation ALK TKI. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed (N)" signifies participants who evaluable for this measure with a follow up of 5 years post index date. Reporting groups with "N" =0 signifies that no participant had a follow up of 5 years post index date. | Posted | Number | Percentage of participants | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 5 Years From Index Date: Based on Chemotherapy Status | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported in this outcome measure. Results were reported based on chemotherapy status. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure with a follow up of 5 years post index date. | Posted | Number | Percentage of participants | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 5 Years From Index Date: Based on CNS Metastases Status | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported in this outcome measure. Results were reported based on CNS metastases status. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure with a follow up of 5 years post index date. | Posted | Number | Percentage of participants | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, 1 Line of ALK TKI Treatment | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, participants who received 1 line of ALK TKI treatment, were reported. Reporting arms were based on type of first line ALK TKI treatment, with or without chemotherapy. ALK TKIs considered were crizotinib, alectinib, ceritinib. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure with a follow up of 5 years post index date. Reporting arm with "Overall Number of Participants Analyzed" = 0, signifies that no participant had a follow up of 5 years post index date. | Posted | Number | Percentage of participants | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, 2 Lines of ALK TKI Treatment | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, participants who received 2 lines of ALK TKI treatment, were reported. Reporting arms were based on type of first line ALK TKI treatment and second line of ALK TKI treatment, with or without chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed (N)" signifies participants who evaluable for this measure with a follow up of 5 years post index date. Reporting groups with "N" =0 signifies that no participant had a follow up of 5 years post index date. | Posted | Number | Percentage of participants | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, 3 Lines of ALK TKI Treatment | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, participants who received 3 lines of ALK TKI treatment. Reporting arms were based on type of first line ALK TKI treatment, second line of ALK TKI treatment, and third line of ALK TKI treatment, with or without chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed (N)" signifies participants who evaluable for this measure with a follow up of 5 years post index date. Reporting groups with "N" =0 signifies that no participant had a follow up of 5 years post index date. | Posted | Number | Percentage of participants | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, More Than or Equal to (>=) 4 Lines of ALK TKI Treatment | Participants alive after five years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, data is reported for participants who received >=4 lines of ALK inhibitor treatment with or without chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure with a follow up of 5 years post index date. | Posted | Number | Percentage of participants | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 6 Years From Index Date: Based on Treatment Cohort Groups | Results were reported for treatment cohort groups based on generation of ALK treatment and were as following: Group A1 = chemotherapy + crizotinib (first generation ALK TKI) + any second (2nd) generation ALK TKI; Group A2 = crizotinib + any 2nd generation ALK TKI; Group B1: chemotherapy + crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group B2 = crizotinib + any 2nd generation ALK TKI + any other 2nd generation ALK TKI; Group C1 = chemotherapy + crizotinib + any 2nd generation ALK TKI + lorlatinib (third generation ALK TKI); Group C2: crizotinib + any 2nd generation ALK TKI + lorlatinib and Group D1 = any 2nd generation ALK TKI + any other 2nd generation ALK TKI. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed (N)" signifies participants who evaluable for this measure with a follow up of 6 years post index date. Reporting groups with "N" =0 signifies that no participant had a follow up of 6 years post index date. | Posted | Number | Percentage of participants | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 6 Years From Index Date: Based on Chemotherapy Status | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported in this outcome measure. Results were reported based on chemotherapy status. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure with a follow up of 6 years post index date. | Posted | Number | Percentage of participants | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 6 Years From Index Date: Based on CNS Metastases Status | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported in this outcome measure. Results were reported based on CNS metastases status. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure with a follow up of 6 years post index date. | Posted | Number | Percentage of participants | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 6 Years From Index Date: Based on ALK Sequencing, 1 Line of ALK TKI Treatment | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, participants who received 1 line of ALK TKI treatment, were reported. Reporting arms were based on type of first line ALK TKI treatment, with or without chemotherapy. ALK TKIs considered were crizotinib, alectinib, ceritinib. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure with a follow up of 6 years post index date. Reporting arm with "Overall Number of Participants Analyzed" = 0, signifies that no participant had a follow up of 6 years post index date. | Posted | Number | Percentage of participants | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 6 Years From Index Date: Based on ALK Sequencing, 2 Lines of ALK TKI Treatment | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, participants who received 2 lines of ALK TKI treatment, were reported. Reporting arms were based on type of first line ALK TKI treatment and second line of ALK TKI treatment, with or without chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed (N)" signifies participants who evaluable for this measure with a follow up of 6 years post index date. Reporting groups with "N" =0 signifies that no participant had a follow up of 6 years post index date. | Posted | Number | Percentage of participants | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 6 Years From Index Date: Based on ALK Sequencing, 3 Lines of ALK TKI Treatment | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure OS was reported for participants who received 3 lines of ALK inhibitor treatment. Reporting arms were based on type of first line ALK TKI treatment, second line of ALK TKI treatment, and third line of ALK TKI treatment, with or without chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed (N)" signifies participants who evaluable for this measure with a follow up of 6 years post index date. Reporting groups with "N" =0 signifies that no participant had a follow up of 6 years post index date. | Posted | Number | Percentage of participants | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
| |||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Alive After 6 Years From Index Date: Based on ALK Sequencing, More Than or Equal to (>=) 4 Lines of ALK TKI Treatment | Participants alive after six years from index date (date of first ALK TKI prescription) to the date of death due to any cause or censoring date (latest available date in data), were reported. In this outcome measure, data is reported for participants who received >=4 lines of ALK inhibitor treatment with or without chemotherapy. | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure with a follow up of 6 years post index date. | Posted | Number | Percentage of participants | 6 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) |
|
Not applicable as adverse events not collected during the study
Due to non-interventional nature of study, the minimum criteria for reporting an adverse event (i.e., identifiable participant, identifiable reporter, a suspect product, and event) could not be met; hence, adverse events were not collected and reported.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Participants With No First Line Chemotherapy | Participants included in this arm received at least one filled prescription of ALK TKIs in real world practices, with no first line chemotherapy treatment. ALK TKIs were crizotinib, alectinib, brigatinib, ceritinib, or lorlatinib. | 0 | 0 | 0 | 0 | 0 | 0 |
| EG001 | Participants With First Line Chemotherapy | Participants included in this arm received at least one filled prescription of ALK TKIs in real world practices, along with first line chemotherapy treatment. ALK TKIs were crizotinib, alectinib, brigatinib, ceritinib, or lorlatinib. | 0 | 0 | 0 | 0 | 0 | 0 |
Not provided
Not provided
Due to ethical compliance study team ensured results would not be reported for those cohorts/groups which had less than 5 participants at the index date.
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
| Mar 14, 2022 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D000077547 | Crizotinib |
| C582670 | alectinib |
| C000598580 | brigatinib |
| C586847 | ceritinib |
| C000590786 | lorlatinib |
| ID | Term |
|---|---|
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D000631 | Aminopyridines |
| D011725 | Pyridines |
Not provided
Not provided
|
|
| OG006 |
| Group D1 |
Participants included in this arm received any two second generation ALK TKIs in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| Units | Counts |
|---|---|
| Participants |
|
|
| Ceritinib |
Participants included in this arm received only ceritinib in real world practices. |
| OG003 | Crizotinib + Chemotherapy | Participants included in this arm received crizotinib in real world practices along with chemotherapy. |
| OG004 | Alectinib + Chemotherapy | Participants included in this arm received alectinib in real world practices along with chemotherapy. |
| OG005 | Ceritinib + Chemotherapy | Participants included in this arm received ceritinib in real world practices along with chemotherapy. |
|
|
| OG002 | Crizotinib + Ceritinib | Participants included in this arm received crizotinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices. |
| OG003 | Alectinib + Brigatinib | Participants included in this arm received alectinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices. |
| OG004 | Alectinib + Ceritinib | Participants included in this arm received alectinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices. |
| OG005 | Alectinib + Lorlatinib | Participants included in this arm received alectinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices. |
| OG006 | Ceritinib + Alectinib | Participants included in this arm received ceritinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices. |
| OG007 | Ceritinib + Brigatinib | Participants included in this arm received ceritinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices. |
| OG008 | Ceritinib + Lorlatinib | Participants included in this arm received ceritinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices. |
| OG009 | Crizotinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG010 | Crizotinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG011 | Crizotinib + Ceritinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG012 | Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG013 | Alectinib + Ceritinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG014 | Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG015 | Ceritinib + Alectinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG016 | Ceritinib + Brigatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG017 | Ceritinib + Lorlatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
|
|
Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices.
| OG002 | Crizotinib + Alectinib + Brigatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG003 | Crizotinib + Ceritinib + Alectinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and alectinib as third line ALK TKI treatment, in real world practices. |
| OG004 | Crizotinib + Ceritinib + Lorlatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG005 | Crizotinib + Ceritinib + Brigatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG006 | Crizotinib + Brigatinib + Alectinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and alectinib as third line ALK TKI treatment, in real world practices. |
| OG007 | Crizotinib + Brigatinib + Lorlatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG008 | Alectinib + Brigatinib + Lorlatinib | Participants included in this arm received alectinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG009 | Alectinib + Lorlatinib + Brigatinib | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG010 | Alectinib + Lorlatinib + Ceritinib | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment and ceritinib as third line ALK TKI treatment, in real world practices. |
| OG011 | Ceritinib + Alectinib + Lorlatinib | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG012 | Ceritinib + Alectinib + Brigatinib | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG013 | Crizotinib + Alectinib + Ceritinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, ceritinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG014 | Crizotinib + Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG015 | Crizotinib + Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG016 | Crizotinib + Ceritinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, alectinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG017 | Crizotinib + Ceritinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG018 | Crizotinib + Ceritinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG019 | Crizotinib + Brigatinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, alectinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG020 | Crizotinib + Brigatinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG021 | Alectinib + Brigatinib + Lorlatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG022 | Alectinib + Lorlatinib + Brigatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG023 | Alectinib + Lorlatinib + Ceritinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment, ceritinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG024 | Ceritinib + Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG025 | Ceritinib + Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| OG001 | Group A2 | Participants included in this arm received crizotinib and any second generation ALK TKI in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG002 | Group B1 | Participants included in this arm received chemotherapy, crizotinib and any two second generation ALK TKIs in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG003 | Group B2 | Participants included in this arm received, crizotinib and any two second generation ALK TKIs in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG004 | Group C1 | Participants included in this arm received chemotherapy, crizotinib, any second generation ALK TKI and lorlatinib in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG005 | Group C2 | Participants included in this arm received crizotinib, any second generation ALK TKI and lorlatinib in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG006 | Group D1 | Participants included in this arm received any two second generation ALK TKIs in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
|
|
| Units | Counts |
|---|
| Participants |
|
|
|
|
| OG002 | Ceritinib | Participants included in this arm received only ceritinib in real world practices. |
| OG003 | Crizotinib + Chemotherapy | Participants included in this arm received crizotinib in real world practices along with chemotherapy. |
| OG004 | Alectinib + Chemotherapy | Participants included in this arm received alectinib in real world practices along with chemotherapy. |
| OG005 | Ceritinib + Chemotherapy | Participants included in this arm received ceritinib in real world practices along with chemotherapy. |
|
|
Participants included in this arm received crizotinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices.
| OG002 | Crizotinib + Ceritinib | Participants included in this arm received crizotinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices. |
| OG003 | Alectinib + Brigatinib | Participants included in this arm received alectinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices. |
| OG004 | Alectinib + Ceritinib | Participants included in this arm received alectinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices. |
| OG005 | Alectinib + Lorlatinib | Participants included in this arm received alectinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices. |
| OG006 | Ceritinib + Alectinib | Participants included in this arm received ceritinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices. |
| OG007 | Ceritinib + Brigatinib | Participants included in this arm received ceritinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices. |
| OG008 | Ceritinib + Lorlatinib | Participants included in this arm received ceritinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices. |
| OG009 | Crizotinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG010 | Crizotinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG011 | Crizotinib + Ceritinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG012 | Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG013 | Alectinib + Ceritinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG014 | Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG015 | Ceritinib + Alectinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG016 | Ceritinib + Brigatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG017 | Ceritinib + Lorlatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
|
|
| Crizotinib + Alectinib + Lorlatinib |
Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG002 | Crizotinib + Alectinib + Brigatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG003 | Crizotinib + Ceritinib + Alectinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and alectinib as third line ALK TKI treatment, in real world practices. |
| OG004 | Crizotinib + Ceritinib + Lorlatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG005 | Crizotinib + Ceritinib + Brigatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG006 | Crizotinib + Brigatinib + Alectinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and alectinib as third line ALK TKI treatment, in real world practices. |
| OG007 | Crizotinib + Brigatinib + Lorlatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG008 | Alectinib + Brigatinib + Lorlatinib | Participants included in this arm received alectinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG009 | Alectinib + Lorlatinib + Brigatinib | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG010 | Alectinib + Lorlatinib + Ceritinib | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment and ceritinib as third line ALK TKI treatment, in real world practices. |
| OG011 | Ceritinib + Alectinib + Lorlatinib | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG012 | Ceritinib + Alectinib + Brigatinib | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG013 | Crizotinib + Alectinib + Ceritinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, ceritinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG014 | Crizotinib + Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG015 | Crizotinib + Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG016 | Crizotinib + Ceritinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, alectinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG017 | Crizotinib + Ceritinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG018 | Crizotinib + Ceritinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG019 | Crizotinib + Brigatinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, alectinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG020 | Crizotinib + Brigatinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG021 | Alectinib + Brigatinib + Lorlatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG022 | Alectinib + Lorlatinib + Brigatinib +Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG023 | Alectinib + Lorlatinib + Ceritinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment, ceritinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG024 | Ceritinib + Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG025 | Ceritinib + Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| OG001 |
| Group A2 |
Participants included in this arm received crizotinib and any second generation ALK TKI in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG002 | Group B1 | Participants included in this arm received chemotherapy, crizotinib and any two second generation ALK TKIs in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG003 | Group B2 | Participants included in this arm received, crizotinib and any two second generation ALK TKIs in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG004 | Group C1 | Participants included in this arm received chemotherapy, crizotinib, any second generation ALK TKI and lorlatinib in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG005 | Group C2 | Participants included in this arm received crizotinib, any second generation ALK TKI and lorlatinib in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG006 | Group D1 | Participants included in this arm received any two second generation ALK TKIs in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
|
|
|
|
|
|
| OG002 | Ceritinib | Participants included in this arm received only ceritinib in real world practices. |
| OG003 | Crizotinib + Chemotherapy | Participants included in this arm received crizotinib in real world practices along with chemotherapy. |
| OG004 | Alectinib + Chemotherapy | Participants included in this arm received alectinib in real world practices along with chemotherapy. |
| OG005 | Ceritinib + Chemotherapy | Participants included in this arm received ceritinib in real world practices along with chemotherapy. |
|
|
| OG002 | Crizotinib + Ceritinib | Participants included in this arm received crizotinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices. |
| OG003 | Alectinib + Brigatinib | Participants included in this arm received alectinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices. |
| OG004 | Alectinib + Ceritinib | Participants included in this arm received alectinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices. |
| OG005 | Alectinib + Lorlatinib | Participants included in this arm received alectinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices. |
| OG006 | Ceritinib + Alectinib | Participants included in this arm received ceritinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices. |
| OG007 | Ceritinib + Brigatinib | Participants included in this arm received ceritinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices. |
| OG008 | Ceritinib + Lorlatinib | Participants included in this arm received ceritinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices. |
| OG009 | Crizotinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG010 | Crizotinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG011 | Crizotinib + Ceritinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG012 | Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG013 | Alectinib + Ceritinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG014 | Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG015 | Ceritinib + Alectinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG016 | Ceritinib + Brigatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG017 | Ceritinib + Lorlatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
|
|
| OG002 | Crizotinib + Alectinib + Brigatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG003 | Crizotinib + Ceritinib + Alectinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and alectinib as third line ALK TKI treatment, in real world practices. |
| OG004 | Crizotinib + Ceritinib + Lorlatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG005 | Crizotinib + Ceritinib + Brigatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG006 | Crizotinib + Brigatinib + Alectinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and alectinib as third line ALK TKI treatment, in real world practices. |
| OG007 | Crizotinib + Brigatinib + Lorlatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG008 | Alectinib + Brigatinib + Lorlatinib | Participants included in this arm received alectinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG009 | Alectinib + Lorlatinib + Brigatinib | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG010 | Alectinib + Lorlatinib + Ceritinib | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment and ceritinib as third line ALK TKI treatment, in real world practices. |
| OG011 | Ceritinib + Alectinib + Lorlatinib | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG012 | Ceritinib + Alectinib + Brigatinib | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG013 | Crizotinib + Alectinib + Ceritinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, ceritinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG014 | Crizotinib + Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG015 | Crizotinib + Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG016 | Crizotinib + Ceritinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, alectinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG017 | Crizotinib + Ceritinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG018 | Crizotinib + Ceritinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG019 | Crizotinib + Brigatinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, alectinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG020 | Crizotinib + Brigatinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG021 | Alectinib + Brigatinib + Lorlatinib +Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG022 | Alectinib + Lorlatinib + Brigatinib +Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG023 | Alectinib + Lorlatinib + Ceritinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment, ceritinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG024 | Ceritinib + Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG025 | Ceritinib + Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| OG001 |
| Group A2 |
Participants included in this arm received crizotinib and any second generation ALK TKI in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG002 | Group B1 | Participants included in this arm received chemotherapy, crizotinib and any two second generation ALK TKIs in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG003 | Group B2 | Participants included in this arm received, crizotinib and any two second generation ALK TKIs in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG004 | Group C1 | Participants included in this arm received chemotherapy, crizotinib, any second generation ALK TKI and lorlatinib in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG005 | Group C2 | Participants included in this arm received crizotinib, any second generation ALK TKI and lorlatinib in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
| OG006 | Group D1 | Participants included in this arm received any two second generation ALK TKIs in real world practices. Second generation ALK TKIs considered were alectinib, brigatinib, or ceritinib. |
|
|
|
|
|
|
| OG002 | Ceritinib | Participants included in this arm received only ceritinib in real world practices. |
| OG003 | Crizotinib + Chemotherapy | Participants included in this arm received crizotinib in real world practices along with chemotherapy. |
| OG004 | Alectinib + Chemotherapy | Participants included in this arm received alectinib in real world practices along with chemotherapy. |
| OG005 | Ceritinib + Chemotherapy | Participants included in this arm received ceritinib in real world practices along with chemotherapy. |
|
|
| OG002 | Crizotinib + Ceritinib | Participants included in this arm received crizotinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices. |
| OG003 | Alectinib + Brigatinib | Participants included in this arm received alectinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices. |
| OG004 | Alectinib + Ceritinib | Participants included in this arm received alectinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices. |
| OG005 | Alectinib + Lorlatinib | Participants included in this arm received alectinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices. |
| OG006 | Ceritinib + Alectinib | Participants included in this arm received ceritinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices. |
| OG007 | Ceritinib + Brigatinib | Participants included in this arm received ceritinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices. |
| OG008 | Ceritinib + Lorlatinib | Participants included in this arm received ceritinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices. |
| OG009 | Crizotinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG010 | Crizotinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG011 | Crizotinib + Ceritinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG012 | Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG013 | Alectinib + Ceritinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and ceritinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG014 | Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG015 | Ceritinib + Alectinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and alectinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG016 | Ceritinib + Brigatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and brigatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG017 | Ceritinib + Lorlatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK KI treatment and lorlatinib as second line ALK TKI treatment, in real world practices along with chemotherapy. |
|
|
Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices.
| OG002 | Crizotinib + Alectinib + Brigatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG003 | Crizotinib + Ceritinib + Alectinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and alectinib as third line ALK TKI treatment, in real world practices. |
| OG004 | Crizotinib + Ceritinib + Lorlatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG005 | Crizotinib + Ceritinib + Brigatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG006 | Crizotinib + Brigatinib + Alectinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and alectinib as third line ALK TKI treatment, in real world practices. |
| OG007 | Crizotinib + Brigatinib + Lorlatinib | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG008 | Alectinib + Brigatinib + Lorlatinib | Participants included in this arm received alectinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG009 | Alectinib + Lorlatinib + Brigatinib | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG010 | Alectinib + Lorlatinib + Ceritinib | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment and ceritinib as third line ALK TKI treatment, in real world practices. |
| OG011 | Ceritinib + Alectinib + Lorlatinib | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and lorlatinib as third line ALK TKI treatment, in real world practices. |
| OG012 | Ceritinib + Alectinib + Brigatinib | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment and brigatinib as third line ALK TKI treatment, in real world practices. |
| OG013 | Crizotinib + Alectinib + Ceritinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, ceritinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG014 | Crizotinib + Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG015 | Crizotinib + Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG016 | Crizotinib + Ceritinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, alectinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG017 | Crizotinib + Ceritinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG018 | Crizotinib + Ceritinib + Brigatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, ceritinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG019 | Crizotinib + Brigatinib + Alectinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, alectinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG020 | Crizotinib + Brigatinib + Lorlatinib + Chemotherapy | Participants included in this arm received crizotinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG021 | Alectinib + Brigatinib + Lorlatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, brigatinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG022 | Alectinib + Lorlatinib + Brigatinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG023 | Alectinib + Lorlatinib + Ceritinib + Chemotherapy | Participants included in this arm received alectinib as first line ALK TKI treatment, lorlatinib as second line ALK TKI treatment, ceritinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG024 | Ceritinib + Alectinib + Lorlatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, lorlatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
| OG025 | Ceritinib + Alectinib + Brigatinib + Chemotherapy | Participants included in this arm received ceritinib as first line ALK TKI treatment, alectinib as second line ALK TKI treatment, brigatinib as third line ALK TKI treatment, in real world practices along with chemotherapy. |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|